Journal
Cancer Research Communications
Publication Date
6-5-2024
Volume
4
Issue
6
First Page
1430
Last Page
1440
Document Type
Open Access Publication
DOI
10.1158/2767-9764.CRC-24-0047
Rights and Permissions
Guo Z, Luo J, Mashl RJ, Hoog J, Maiti P, Fettig N, Davies SR, Aft R, Held JM, Govindan R, Ding L, Li S, von Morze C, Wulf GM, Shoghi KI, Ma CX. Evaluation of Copanlisib in Combination with Eribulin in Triple-negative Breast Cancer Patient-derived Xenograft Models. Cancer Res Commun. 2024 Jun 5;4(6):1430-1440. doi: 10.1158/2767-9764.CRC-24-0047 This open access article is distributed under the Creative Commons Attribution 4.0 International (CC BY 4.0) license. © 2024 The Authors; Published by the American Association for Cancer Research
Recommended Citation
Guo, Zhanfang; Luo, Jingqin; Mashl, R Jay; Hoog, Jeremy; Maiti, Piyush; Fettig, Nikki; Davies, Sherri R; Aft, Rebecca; Held, Jason M; Govindan, Ramaswamy; Ding, Li; Li, Shunqiang; von Morze, Cornelius; Shoghi, Kooresh I; Ma, Cynthia X; and et al., "Evaluation of copanlisib in combination with eribulin in triple-negative breast cancer patient-derived xenograft models." Cancer Research Communications. 4, 6. 1430 - 1440. (2024).
https://digitalcommons.wustl.edu/oa_4/3851
Department
ICTS (Institute of Clinical and Translational Sciences)
Additional Links
Supplemental material is available for this article at publisher site.
